Cathepsin L is a major lysosomal cysteine proteinase in mouse and human cells. Despite similar predicted molecular masses, procathepsin L in these two species migrates on SDS/polyacrylamide gels with apparent molecular masses of 39 kDa and 42 kDa respectively. To determine if glycosylation differences account for this discrepancy, and to ascertain whether glycosylation is essential for enzymic activity, mouse and human procathepsins L were expressed at high concentrations in mouse NIH 3T3 cells or in human A43 1 cells after DNA-mediated transfection of cloned DNAs for these enzymes. In pulse-chase studies, human procathepsin L transfectants synthesized and secreted large amounts of enzymically active 42 kDa proenzyme and processed it into 34 kDa and 26 kDa intracellular peptides, a pattern of secretion and processing similar to that seen with endogenous or transfected mouse procathepsin L. Both translation of cloned procathepsin L cDNAs in vitro and Endoglycosidase H treatment of 39 kDa mouse and 42 kDa human procathepsin L resulted in non-glycosylated proteins 2 kDa lower in molecular mass than the untreated proteins for both species. This suggests that glycosylation differences are not responsible for the molecular-mass disparity between the two species. Moreover, Endoglycosidase H-treated mouse enzyme retained full proteolytic activity, indicating that glycosylation of cathepsin L is not essential for enzymic function.
INTRODUCTION
Cathepsins are lysosomal acid proteinases that are believed to play important roles in intracellular protein degradation and turnover [1] , bone remodelling [2] , prohormone activation [3] , cancer metastasis [4] and other disease processes [5] . Although cathepsins are generally targeted to the lysosome by mannose 6-phosphate lysosomal recognition markers [6] , secretory routing of several cathepsin precursors by malignantly transformed cells has been reported. These highmolecular-mass precursors include procathepsin D from oestrogen-receptor-positive breast cancer cells [7] , a procathepsin from pancreatic carcinoma cells [8] and the cysteine proteinases procathepsin B from cancer ascites fluid [9] and breast tumours [10] and the major excreted protein (MEP) of transformed mouse fibroblasts [11] . MEP has been identified as the precursor to mouse cathepsin L by its enzymic properties [12] and by cDNA sequence analysis [13] .
Mouse cDNA and genomic MEP/procathepsin L clones express a full-length 39 kDa protein when transfected into a variety of mammalian cell types, including human cells [13] [14] [15] , and the protein is correctly processed into 29 kDa and 20 kDa forms within these cells. Acid proteinase activity increases significantly in the conditioned medium of cells transfected with cloned mouse MEP/procathepsin L genomic DNA [14] . Transfection of a full-length human procathepsin L cDNA into mouse NIH 3T3 cells results in expression of a 42 kDa protein and two lower-molecular-mass forms that are specifically immunoprecipitated by anti-(human cathepsin L) serum [15] . Proteolytic activity in media from human procathepsin L cDNA transfectants has not previously been assessed.
Although the molecular-mass difference between the 39 kDa mouse and 42 kDa human bands detected on SDS/polyacrylamide-gel electrophoresis is 3 kDa, the predicted non-glycosylated molecular mass for both proteins is 35.8 kDa, on the basis of the deduced amino acid composition. This molecular-mass dispr rity suggested that mouse and human procathepsins L might be glycosylated differently. Since mouse and human procathepsins L of the appropriate molecular masses may be expressed from cDNAs transfected into either mouse or human cells, such a glycosylation difference would not be cell-type-specific.
The role of glycosylation in cathepsin L proteinase activity has not been established. Concanavalin A columns do not bind all of the applied proteinase activity of purified human, rabbit or rat liver cathepsin L [16] [17] [18] . This suggests the possibility that some of the active purified cathepsin L in these preparations is not glycosylated. Several non-cysteine proteinases clearly Abbreviations used: MEP, major excreted protein of transformed mouse fibroblasts; Cbz-, benzyloxycarbonyl-; -NH-Mec, 4-methylcoumarin-7-ylamide.
have enzymic function independent of glycosylation, since they retain activity when expressed as recombinant non-glycosylated enzymes in Escherichia coli [19] [20] [21] .
Mouse and human procathepsins L were expressed in mouse and human cells by co-transfection with a multidrug-resistance cDNA, which is selectable and amplifiable [15] . The high expression of procathepsin L in the human transfectants allowed us to examine the intracellular processing of the human procathepsin. We also evaluated the role played by glycosylation in procathepsin L proteolytic activity and in molecular-mass differences between species. We report that (1) active mouse and human procathepsins L were overexpressed by transfectants, (2) human procathepsin L secretion and processing into three intracellular forms was kinetically very similar to the secretion and processing previously described for the mouse analogue, (3) glycosylation did not account for the species differences in proenzyme molecular mass, and (4) glycosylation was not necessary for proteinase activity. [23] with pHaMDRI +pcosMEPSA (NIH) or with pHaMDR1 + pHaMEPh (A43 1), and were selected with 60 ng or 6 ng ofcolchicine/ml respectively, as described previously [15] .
MATERIALS AND METHODS
To amplify the transferred DNAs, individual colonies (NIH-MEPm) or mixed populations (A431-MEPh) of cells were grown in increasing amounts of colchicine until NIH-MEPm clones were at 1 jug of colchicine/ml and A431-MEPh cells were at 400 ng of colchicine/ml. [25] . Gels were stained with Coomassie Blue, then treated with 2,5-diphenyloxazole in dimethyl sulphoxide [26] or Autofluor (National Diagnostics, Manville, NJ, U.S.A.), dried and fluorographed with preflashed X-Omat AR film (Kodak) at -70°C. "4C-labelled molecular-mass markers were myosin (200 kDa), phosphorylase b (92.5 kDa), bovine serum albumin (69 kDa), ovalbumin (46 kDa), carbonic anhydrase (30 kDa) and lysozyme (14.3 kDa) (Amersham). RNA synthesis and translation in vitro RNA including the complete protein-coding regions for mouse procathepsin L and for human procathepsin L was synthesized from templates containing subclones of mouse [13] and human [22] cDNA clones in pGEM-3 (Promega Biotec, Madison, WI, U.S.A.). The templates were first cleaved with HindIII to linearize the DNA, then RNA was synthesized with the use of T7 RNA polymerase as described by the manufacturer (Promega Biotec). The RNA polymerase was allowed to react for 2 h at 37°C before RQ1 DNAase (Promega Biotec) was added (1 unit/#g of DNA) for 15 min at 37°C to degrade the DNA template. The RNA was extracted and precipitated with ethanol. Procathepsin L proteins were synthesized from this RNA by using a rabbit reticulocyte translation system in vitro (Bethesda Research Laboratories) in the presence of [35S]methionine (Amersham). The reaction conditions were as recommended by the manufacturer and included 0.1 #Ci of [35S]methionine/,l and either no RNA (control) or 50 ng of RNA/,u per reaction. The reaction was allowed to proceed for 1 h at 30 "C, after which the RNA was degraded with RNAase A. Then 104 trichloroacetic acid-precipitable c.p.m. of total extract were separated by electrophoresis on an SDS/ 12 %-polyacrylamide gel. The gel was prepared for fluorography as described above. Endoglycosidase H treatment Media from 80 %-confluent cell cultures in a 100 mm culture dish (radiolabelled) and in six 75 cm2 culture flasks were pooled and the secreted proteins were precipitated with (NH4)2SO4 as described above. Concentrated proteins were then diluted with sodium phosphate buffer, pH 6.5, to a final concentration of 0.05 M and incubated for 18-20 h at 37 "C in the presence or in the absence of Endoglycosidase H from Staphylococcus griseus (Sigma Chemical Co.) (1 munit/ 1.8 #g ofprotein).
Samples were then tested for proteolytic activity or immunoprecipitated as described above. Concanavalin A-Sepharose column chromatography
The 0.7 cm x 4 cm columns (Bio-Rad Laboratories, Richmond, CA, U.S.A.) were packed with 0.5 ml (5 mg) of concanavalin A-Sepharose (Pharmacia) and rinsed with 20 ml of buffer (25 mM-Hepes buffer, pH 7.5, containing 1 mM-MnCl2, 1 mM-CaCl2 and 1 mM-MgCl2). Equal radioactivity amounts of Endoglycosidase Htreated and untreated concentrated KNIH 35S-labelled medium samples (1 ml), which had been dialysed against the same buffer, were applied to the columns and washed with 5 ml of buffer. Column effluents and 1 ml samples not applied to the column were immunoprecipitated and either electrophoresed or assayed for proteolytic activity.
Proteinase activity
Proteinase activity of NIH-MDR, NIH-MEPm, A431 and A43 1-MEPh concentrated conditioned media against 5 /LM-Cbz-Phe-Arg-NH-Mec (Sigma Chemical Co.), the optimal synthetic substrate for cathepsin L, was assayed as described by Troen et al. [14] . Although procathepsin L is active at pH 5.5 [12] , in practice we first activated the proenzyme at pH 3.0 and 37 "C for 30 s, which causes rapid conversion of procathepsin L into the more active mature enzyme. Continuous-rate enzyme activity was then assayed at pH 5.5 and 30 'C. Leupeptin (Sigma Chemical Co.), a reversible inhibitor of cysteine proteinases, was added to the reaction mixture at a final concentration of 0.1 ,ug/ml for proteinase inhibition. Protein concentration was measured by the Bio-Rad protein microassay method, with bovine serum albumin as standard. Proteinase activity was expressed as the rate of reaction during the initial linear portion of the assay in arbitrary units/s, divided by the number of cells at 80 % monolayer confluence (3 x 106 NIH cells/75 cm2 culture flask and 5 x 106 A431 cells/75 cm2 culture flask).
Proteinase activity of concentrated KNIH-conditioned-medium immunoprecipitation complexes was assayed against 5 ,M-Cbz-Phe-Arg-NH-Mec as above, except that samples were maintained at 30 'C at pH 5.5 for 28 min. Samples were vortex-mixed every 2 min to keep the Protein A-Sepharose complexes suspended. Reactions were stopped by centrifuging immunoprecipitation complexes in a microcentrifuge and transferring reaction mixture supernatants to a fluorescence spectrophotometer for activity measurement. E-64 (Sigma Chemical Co.), an irreversible specific cysteine-proteinase inhibitor, was added at a final concentration of 2 /tM for proteinase inhibition. Activity units are expressed as pmol of substrate hydrolysed/30 min, after correction for the relative amount of procathepsin L in each sample by densitometry of electrophoresed samples (Fig. 5) .
RESULTS

Expression of procathepsin L
To express mouse and human procathepsins L (MEP) at high concentrations in mouse and human cells, we co- (pHaMDRI + pHaMEPh) was approx. 10-fold greater than by non-transfected A431 cells (Fig. 1) . Processing and secretion of human procathepsin L To examine the intracellular processing and secretion of human procathepsin L, A431-MEPh cells were pulselabelled for 15 min with [35S]methionine, then chased with fresh medium containing unlabelled methionine for various lengths of time. The fluorograms in Fig. 2 reveal that human procathepsin L was sequentially processed into 34 kDa and 26 kDa forms within transfected A431 cells (Fig. 2a) and that approx. 50 % of the 42 kDa precursor protein was secreted by these cells over 12 h (Fig. 2b) . The 26 kDa intracellular form probably corresponds to the 25 kDa form of purified human liver cathepsin L previously observed on SDS/polyacrylamide-gel electrophoresis under reducing conditions [16] . The processing and secretion kinetics of transfected human procathepsin L appeared to be nearly identical with the kinetics described for endogenous mouse procathepsin L in transformed mouse KNIH cells [28] . Processing of precursor enzyme into two lower-molecular-mass intra- Procathepsin L molecular mass and glycosylation To determine the molecular mass of mouse and human procathepsin L in the absence of post-translational covalent modifications, procathepsin L RNA was synthesized in vitro and translated in vitro in a rabbit reticulocyte system. As shown in Fig. 3 , translation of mouse and human procathepsin L RNA in vitro resulted in the production of major species of unmodified mouse and human procathepsins L that migrated at 37 kDa and 40 kDa respectively on SDS/polyacrylamide-gel electrophoresis. Therefore the 3 kDa difference in molecular mass between the mouse and human procathepsins was retained when the major translation products were compared (Fig. 3) . This result indicates that the molecularmass difference was not due to differences in posttranslational modification.
This result was confirmed by enzymic deglycosylation of procathepsin L expressed in mammalian cells with Endoglycosidase H, which cleaves high-mannose sugar groups from asparagine-linked glycoproteins, leaving only a single N-acetylglucosamine residue attached to asparagine. In Fig. 4 , 2 kDa shifts in the molecular masses of radiolabelled procathepsin L from both mouse (39 kDa to 37 kDa) and human (42 kDa to 40 kDa) conditioned media after Endoglycosidase H treatment are shown.
To prove that Endoglycosidase H treatment of procathepsin L results in complete deglycosylation, concentrated radiolabelled medium from transformed mouse KNIH cells was incubated with Endoglycosidase H, then passed over a concanavalin A-Sepharose column, which binds glycoproteins. Column effluent was subjected to immunoprecipitation with specific antiserum, and immunoprecipitation complexes were either electrophoresed or assayed for enzymic activity. SDS/polyacrylamide-gel-electrophoretic analysis (Fig. 5) 3 and 4) . It was also not eluted by washing with methyl a-mannoside (results not shown). It is therefore believed to be non-specifically bound to the column. passed through the column, whereas over 600% of the treated proenzyme was recovered from the column effluent. Mouse procathepsin L in the Endoglycosidase H-treated column effluent migrated at 37 kDa, indicating that the 2 kDa decrease in molecular mass observed after Endoglycosidase H treatment in the previous experiment (Fig. 4) (Fig.  4) . Although neither the substrate nor the inhibitor in this experiment is absolutely specific for cathepsin L, the higher proteinase activity in medium from procathepsin L transfectant cells that oversecrete immunoprecipitable procathepsin L relative to control cells can be attributed to expression of the transfected procathepsin L. Endoglycosidase H treatment did not result in diminished proteolytic activity in medium from either cell line (Table  1) , despite the fact that the sugar had been removed by this treatment (Fig. 4) [32, 33] . In the present paper we have shown that glycosylation has no apparent effect on enzymic activity of secreted mouse procathepsin L. We have also recently expressed purified recombinant human procathepsin L from a cloned cDNA fragment in Escherichia coli (S. M. Smith & M. M. Gottesman, unpublished work). This recombinant enzyme is proteolytically active with a similar specific activity to that of purified human liver cathepsin L [16] , confirming that glycosylation of human cathepsin L is not required for proteolytic activity.
The deduced amino acid sequences of mouse and human procathepsins L [22] indicate the presence of two and one potential asparagine-linked glycosylation sites respectively. Judged by the same 2 kDa decrease in molecular mass observed for both mouse and human procathepsins L after enzymic deglycosylation or translation in vitro, both enzymes carry an equivalent number of sugar residues. This suggests the possibility that only one of two potential glycosylation sites on mouse procathepsin L is utilized.
The predicted molecular masses of mouse and human procathepsins L are the same, yet the molecular masses observed on SDS/polyacrylamide-gel electrophoresis differ by 3 kDa, regardless of whether expression is in mouse or human cells. Moreover, this 3 kDa difference persists in the non-glycosylated forms of the two proteins, indicating that glycosylation cannot account for the difference in SDS/polyacrylamide-gel-electrophoretic migration. The most plausible explanation for this phenomenon is that different charges on the two proteins result in different gel mobilities. On the basis of the deduced amino acid compositions of the precursor and processed cathepsin L peptides, all three forms of the mouse enzyme are more basic than their human enzyme counterparts, each mouse form having seven to ten fewer net acidic groups. Since basic proteins tend to migrate relatively faster on SDS/polyacrylamide-gel electrophoresis than do acidic proteins [34] , presumably owing to increased SDS binding, the faster mobility of each of the mouse cathepsin L forms (39 kDa, 29 kDa and 20 kDa) relative to their human cathepsin L counterparts (42 kDa, 34 kDa and 26 kDa) is consistent with the more basic isoelectric point of the mouse enzyme [24] .
These studies establish that it is possible to express human and mouse procathepsins L at high concentrations in cultured cells after DNA-mediated transfection of appropriate cloned sequences. The secretion and processing of mouse and human procathepsins L are virtually identical, and the species differences in molecular mass are not due to differences in glycosylation. Glycosylation is not essential for enzymic activity of cathepsin L from either species.
